Review





Similar Products

obesity primary antibodies against atf3  (ABclonal Biotechnology)
94
ABclonal Biotechnology obesity primary antibodies against atf3
Obesity Primary Antibodies Against Atf3, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/obesity/ATF3+Rabbit+pAb/pm42469432-92-26-31
Average 94 stars, based on 1 article reviews
obesity primary antibodies against atf3 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
human antibody arrays  (RayBiotech inc)
90
RayBiotech inc human antibody arrays
Human Antibody Arrays, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/obesity/Human+Obesity+Array+Q1/pm42229831-82-9-19
Average 90 stars, based on 1 article reviews
human antibody arrays - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
obese  (Inotiv)
93
Inotiv obese
Obese, supplied by Inotiv, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/obesity/Zucker+obese+rats/pm42451064-60-6-21
Average 93 stars, based on 1 article reviews
obese - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
human obesity array c1  (RayBiotech inc)
94
RayBiotech inc human obesity array c1
Human Obesity Array C1, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/obesity/Human+Obesity+Array+C1/pm42342067-505-20-25
Average 94 stars, based on 1 article reviews
human obesity array c1 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
glp 1 obesity drugs  (Novo Nordisk)
86
Novo Nordisk glp 1 obesity drugs
Glp 1 Obesity Drugs, supplied by Novo Nordisk, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/obesity/1+agonist+glp+receptor/pm42289174-172-15-4
Average 86 stars, based on 1 article reviews
glp 1 obesity drugs - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
diet induced obesity experiment  (Jackson Laboratory)
86
Jackson Laboratory diet induced obesity experiment
Rec2-exendin-4 gene therapy improves metabolic and behavioral functions <t>in</t> <t>diet-induced</t> obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.
Diet Induced Obesity Experiment, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/obesity/26+6j+c57bl+diet+induced+male+mouse+obese+plasma+weeks+young/pmc13148920-306-1-9
Average 86 stars, based on 1 article reviews
diet induced obesity experiment - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
obesity focused metsera  (Pfizer Inc)
86
Pfizer Inc obesity focused metsera
Rec2-exendin-4 gene therapy improves metabolic and behavioral functions <t>in</t> <t>diet-induced</t> obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.
Obesity Focused Metsera, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/obesity/focused+metsera+obesity/pm42270835-32-10-14
Average 86 stars, based on 1 article reviews
obesity focused metsera - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
arw pediatric obesity i disease specifc programmetm  (Adelphi Technology Inc)
86
Adelphi Technology Inc arw pediatric obesity i disease specifc programmetm
Rec2-exendin-4 gene therapy improves metabolic and behavioral functions <t>in</t> <t>diet-induced</t> obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.
Arw Pediatric Obesity I Disease Specifc Programmetm, supplied by Adelphi Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/obesity/disease+muc+programmetm+real+specific+world/pm42241377-3300-18-6
Average 86 stars, based on 1 article reviews
arw pediatric obesity i disease specifc programmetm - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
pediatric obesity i disease specifc programmetm  (Adelphi Technology Inc)
86
Adelphi Technology Inc pediatric obesity i disease specifc programmetm
Rec2-exendin-4 gene therapy improves metabolic and behavioral functions <t>in</t> <t>diet-induced</t> obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.
Pediatric Obesity I Disease Specifc Programmetm, supplied by Adelphi Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/obesity/disease+muc+programmetm+real+specific+world/pm42241377-3275-9-8
Average 86 stars, based on 1 article reviews
pediatric obesity i disease specifc programmetm - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
obesity disease specifc programmetm  (Adelphi Technology Inc)
86
Adelphi Technology Inc obesity disease specifc programmetm
Rec2-exendin-4 gene therapy improves metabolic and behavioral functions <t>in</t> <t>diet-induced</t> obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.
Obesity Disease Specifc Programmetm, supplied by Adelphi Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/obesity/disease+muc+programmetm+real+specific+world/pm42241377-6252-9-8
Average 86 stars, based on 1 article reviews
obesity disease specifc programmetm - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


Rec2-exendin-4 gene therapy improves metabolic and behavioral functions in diet-induced obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.

Journal: Molecular Therapy Advances

Article Title: Low dose systemic AAV-exendin-4 gene therapy for Prader-Willi syndrome and dietary obesity

doi: 10.1016/j.omta.2026.201718

Figure Lengend Snippet: Rec2-exendin-4 gene therapy improves metabolic and behavioral functions in diet-induced obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.

Article Snippet: For diet-induced obesity experiment, C57BL/6 mice were purchased from Jackson Laboratory.

Techniques: Injection, Staining

Rec2-exendin-4 and Rec2-exendin-4-HA reverses diet-induced obesity and associated metabolic dysfunction (A) Body weight. Mixed ANOVA with Sidak’s multiple comparisons test. ∗ p < 0.05 Ex4 and Ex4-HA versus GFP. (B) Final body weight. (C) Weight gain. Two-way RM-ANOVA with Sidak’s multiple comparisons test. ∗∗∗ p < 0.001 Ex4 and Ex4-HA versus GFP. (D) Total weight gain. (E) Average food intake measured week 1–4 post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Indirect calorimetry at 7–8 weeks post injection. Data are means ± SEM. Sample size: GFP n = 4, Ex4 n = 5, Ex4-HA n = 5. Individual values are shown in graph. One-way ANOVA with Tukey’s post hoc test to adjust pairwise comparisons of all groups. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Journal: Molecular Therapy Advances

Article Title: Low dose systemic AAV-exendin-4 gene therapy for Prader-Willi syndrome and dietary obesity

doi: 10.1016/j.omta.2026.201718

Figure Lengend Snippet: Rec2-exendin-4 and Rec2-exendin-4-HA reverses diet-induced obesity and associated metabolic dysfunction (A) Body weight. Mixed ANOVA with Sidak’s multiple comparisons test. ∗ p < 0.05 Ex4 and Ex4-HA versus GFP. (B) Final body weight. (C) Weight gain. Two-way RM-ANOVA with Sidak’s multiple comparisons test. ∗∗∗ p < 0.001 Ex4 and Ex4-HA versus GFP. (D) Total weight gain. (E) Average food intake measured week 1–4 post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Indirect calorimetry at 7–8 weeks post injection. Data are means ± SEM. Sample size: GFP n = 4, Ex4 n = 5, Ex4-HA n = 5. Individual values are shown in graph. One-way ANOVA with Tukey’s post hoc test to adjust pairwise comparisons of all groups. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: For diet-induced obesity experiment, C57BL/6 mice were purchased from Jackson Laboratory.

Techniques: Injection